Medtronic acquires SPR Therapeutics for $650M, bolstering neuromodulation portfolio

What happened

Medtronic announced its intent to acquire SPR Therapeutics for $650 million in cash, adding temporary peripheral nerve stimulation (PNS) technology to its neuromodulation offerings for chronic pain. The deal is a bolt-on acquisition relative to Medtronic's scale, expanding its pain management capabilities but not altering the company's near-term competitive dynamics. The DeepValue report maintains a WAIT rating, citing valuation at P/E 26.6 with limited room for error, while the Applied litigation ($382M jury verdict with trebling risk) and PFA pricing pressure from Abbott's Volt launch remain key overhangs. The acquisition reinforces Medtronic's strategic pivot toward growth categories but does not shift the immediate catalysts: FY26 Q4 results (May 20) and litigation clarity. Overall, the deal is a positive but incremental step, unlikely to move the stock meaningfully given the larger risks in the base case.

Implication

Investors should view this as a modest bolt-on that diversifies the neuromodulation portfolio but does not change the investment thesis. The $650M cash outlay is manageable given Medtronic's $2.3B quarterly free cash flow, but it reduces capital for share buybacks or debt reduction. The deal underscores Medtronic's focus on high-growth adjacencies, yet the core growth driver — PFA — faces intensifying competition from Abbott Volt, which could compress margins. The Applied litigation overhang remains, with a potential trebled $1.15B judgment plus injunction risk that could disrupt business. Until FY26 Q4 results confirm PFA share gains without pricing pressure and litigation posture clarifies, the risk/reward remains unattractive at current multiples.

Thesis delta

The acquisition of SPR Therapeutics adds a new revenue stream in temporary PNS for chronic pain, marginally enhancing Medtronic's neuromodulation portfolio. However, it does not resolve the primary near-term catalysts and risks: PFA pricing pressure, Hugo commercialization, and the Applied litigation overhang. The thesis remains wait for FY26 Q4 results and clarity on litigation before committing.